Full-Time

Senior Director

Quality Systems GTS

Posted on 9/3/2025

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$203.9k - $273.9k/yr

+ Bonus + Incentive Compensation + Equity Awards

Princeton, NJ, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Risk Management
Data Analysis
Requirements
  • Bachelor’s degree in Engineering, Computer Science or related technological field and minimum 10 years of relevant work experience in building, configuring, and supporting Quality Assurance and/or Quality Control systems, or
  • Master’s Degree in Engineering, Computer Science or related technological field and minimum 7 years of relevant work experience in building, configuring, and supporting Quality Assurance and/or Quality Control systems.
  • Strong experience with software lifecycle methodologies, 21CFR Part 11 compliance, and GxP computer systems validation (CSV).
  • Previous experience in a manufacturing or operations environment.
  • Strong experience with any two of the following platforms: Veeva, LIMS, CDS and/or other Quality platforms. validation practices (GAMP).
  • Experience authoring and reviewing standard operating procedures, on-the-job-trainings, and other controlled documents.
  • Experience in managing small to medium-sized projects and outside vendors.
Responsibilities
  • Serve as the GTS Quality Business Partner and interface with the global Quality organization and develop effective business relationships with key Quality leaders and stakeholders
  • Act as the principal interface between Quality and GTS to solicit and formulate and manage vendor proposals/ contracts, engage cross-functional stakeholders, execute technology projects
  • Develop strong collaborative relationships with Quality & GTS colleagues to leverage shared services where applicable, drive economies of scale and value realization through process and technology harmonization that aligns with the global GTS strategy
  • Review and assess demand requests, explore new ideas and enhancements, evaluate legal/ regulatory requirements relating to data integration and analytics
  • Lead/support projects and ongoing business-driven change initiatives leading to value driven business cases and well-defined implementation plans
  • Partner with key stakeholders to ensure robust investment governance and measuring project outcomes
  • Work closely with manufacturing sites to lead the development of business cases for programs and projects, define measurable business outcomes, deploy, maintain and support QA & QC solutions
  • Generate and maintain a strategic digital roadmap for the Quality capability, with ongoing demand management, resource management, release planning and drive incremental capabilities
  • Monitor external industry trends and supplier capabilities with a view for continuous improvement
  • Experience in developing strategies for new product introduction and new technology deployment
  • Support strategy, deployment and quality operations at the manufacturing plants in China & US
  • Understands the global Quality, risk, and regulatory environment to plan activities for compliance with existing and new regulations.
Desired Qualifications
  • Strong team player who engages with peers to define, sponsor, and execute continuous improvements.
  • Solid leadership, technical writing, and communication/presentation skills.
  • Strong experience in business analysis and process mapping.
  • Ability to quickly assimilate knowledge of new platforms, languages, tools and technologies.

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • TEVIMBRA Priority Review and Breakthrough Designation for HER2+ gastric cancer expands addressable market.
  • Q1 2026 revenue of $1.5B exceeds forecasts; BRUKINSA sales grew 38% year-over-year.
  • First GAAP profitability achieved in 2025 with $942M free cash flow generation.

What critics are saying

  • AbbVie's ABBV-599 Phase 3 readout H2 2026 directly challenges BRUKINSA's CLL dominance.
  • Merck's pembrolizumab FDA label expansion blocks TEVIMBRA's gastric cancer approval pathway.
  • Dr. Reddy's ibrutinib generic captures 15% CLL market share with 25% price discounts.

What makes BeOne unique

  • BRUKINSA demonstrates 74% six-year PFS and 84% OS in frontline CLL versus competitors.
  • Only BTK inhibitor showing superiority versus ibrutinib in head-to-head clinical trials.
  • Advanced ADC platform with multispecific antibodies and proprietary payload chemistry for tumor targeting.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

5%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...

INACTIVE